Stockscreener 앱 받기
1.06
0.93%
-0.01
시간 외 거래:
1.07
0.01
+0.94%
Revelation Biosciences Inc 주식(REVB)의 최신 뉴스
Revelation Biosciences (REVB) Faces Slight Decline as Key Support Levels Are TestedFibonacci Entry Signals - Newser
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Press & Sun-Bulletin
Revelation Biosciences Q1 2026 Earnings: EPS Miss Highlights Ongoing Pre-Revenue StageStock Analysis Community - Newser
Revelation Biosciences Inc. (REVB) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Continues DevelopmentEarnings Yield Spread - Newser
Revelation Biosciences (REVB) Consolidates Near Key Support at $1.03Institutional Grade Picks - Newser
REVB Stock Price, Quote & Chart | REVELATION BIOSCIENCES INC (NASDAQ:REVB) - ChartMill
Why Revelation Biosciences Stock Jumped Today as Traders Eye Its Kidney-Drug Bet - Bez Kabli
Revelation Biosciences (REVB) Stock Forum and Discussion - Moomoo
Revelation Biosciences (REVB) Climbs +4.51% — Resistance at $1.07 in Focus 2026-05-18Community Risk Signals - Newser
Revelation Biosciences, Inc.Common Stock (NQ: REVB - The Chronicle-Journal
Armistice Capital reports 323,241 REVB shares (REVB) — 7.80% stake disclosed - Stock Titan
Revelation Biosciences announces pricing of $4M public offering - MSN
TradingKey - TradingKey
Revelation Biosciences (NASDAQ: REVB) seeks wide reverse split authority in 2026 proxy - Stock Titan
Revelation Biosciences releases proxy materials with CEO update - Investing.com
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders - The Joplin Globe
How one 300-patient trial could unlock a new acute kidney injury treatment - Stock Titan
The edge Revelation Biosciences (REVB) has in a competitive landscape (Risk Aversion) 2026-05-08Verified Stock Signals - Newser
EX-99.1 - SEC.gov
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 - Times Argus
Q1 2026 results for Revelation Biosciences (NASDAQ: REVB) detailed - Stock Titan
FDA agrees to single Gemini study for acute kidney injury - Stock Titan
BRIEF-Revelation Biosciences Inc Q1 EPS USD -2.71 - TradingView
Revelation Biosciences (REVB) Q1 loss widens as cash runway and going concern risks emerge - Stock Titan
Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Revelation Biosciences Inc expected to post a loss of $1.15 a shareEarnings Preview - TradingView
Revelation Biosciences (REVB) CEO has shares sold to cover tax withholding - Stock Titan
Revelation Biosciences (REVB) CFO reports tax-withholding share sale via trust - Stock Titan
Revelation Biosciences (NASDAQ: REVB) asks shareholders to approve wide reverse split - Stock Titan
REVB Revelation Biosciences reports vastly wider Q4 2025 loss than estimates, shares end flat for the trading day.Beat Estimates - newser.com
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development - The Sheboygan Press
REVB Revelation Biosciences posts massive Q4 2025 EPS shortfall on zero revenue, shares remain unchanged.Operational Risk - Cổng thông tin điện tử tỉnh Tây Ninh
REVB (Revelation Biosciences Inc.) posts drastically wider than expected Q4 2025 loss, sending its stock down 4.76% in today’s trading.EBITDA Margin - UBND thành phố Hải Phòng
REVB (Revelation Biosciences Inc.) falls 4.58% today after Q4 2025 EPS misses estimates by a staggering 541.5%. - UBND thành phố Hải Phòng
Revelation Biosciences Stock Sinks 12% After Reverse Split Reveal; Retail Traders Eye ‘Bigger News’ - MSN
Aug Setups: Is Revelation Biosciences Inc Equity Warrant showing insider buyingQuarterly Earnings Summary & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Aug Sectors: What is the Moat Score of Revelation Biosciences Inc2026 Momentum Check & Advanced Technical Analysis Signals - baoquankhu1.vn
Forecast Cut: Can Revelation Biosciences Inc Equity Warrant grow without dilution2026 Catalysts & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Aug Decliners: What are the risks of holding Revelation Biosciences IncQuarterly Profit Report & Daily Technical Forecast Reports - baoquankhu1.vn
REVB Technical Analysis & Stock Price Forecast - Intellectia AI
Fed Meeting: Will Revelation Biosciences Inc Equity Warrant benefit from green energy policiesEarnings Summary Report & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Support Test: What is Revelation Biosciences Inc Equity Warrants valuation compared to sector2026 Top Decliners & Community Shared Stock Ideas - baoquankhu1.vn
Stock Market Recap: Can Revelation Biosciences Inc keep up with sector leadersWeekly Profit Analysis & Smart Swing Trading Alerts - baoquankhu1.vn
US Market Wrap: Is Revelation Biosciences Inc Equity Warrant showing insider buyingWeekly Trade Analysis & Real-Time Price Movement Reports - baoquankhu1.vn
Revelation Biosciences forms advisory board for AKI trial By Investing.com - Investing.com Australia
Chart Watch: Does Revelation Biosciences Inc Equity Warrant stock benefit from AI growthDip Buying & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Revelation Biosciences Forms Acute Kidney Injury Advisory Board - National Today
Revelation Biosciences forms advisory board for AKI trial - Investing.com
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board - ACCESS Newswire
0.98%
0.12%
자본화:
|
볼륨(24시간):